Immunomodulatory News and Research

RSS

Spatial transcriptomics study elucidates cellular dynamics during heart transplant rejection

A new study that explores gene expression during heart transplant rejection marks a step forward for precision medicine approaches to treat organ rejection.

10 Aug 2026

Omalizumab beats multiallergen oral immunotherapy in multifood allergy trial

Omalizumab demonstrates higher treatment success for multifood allergies compared to oral immunotherapy, with fewer adverse events impacting patient retention.

30 Jul 2026

Too little or too much iodine may push immunity off balance

This narrative review finds that adequate iodine supports thyroid hormone signaling, leukocyte metabolism, antioxidant defenses, and antimicrobial activity in humans and domesticated mammals. Both deficiency and sustained excess may impair immunity or promote thyroid inflammation, but precise immune-specific intake thresholds remain uncertain.

27 Jul 2026

New study redefines high risk criteria for multiple myeloma

Researchers have found that with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria for identifying patients with poor odds of survival.

20 Jul 2026

Study reports a counterintuitive new approach to treating mesothelioma

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

14 Jul 2026

Review highlights macrophages as key drivers of chronic transplant rejection

A comprehensive review led by Professors Malgorzata Kloc and Xian Chang Li at the Immunobiology and Transplant Science Center of Houston Methodist Hospital in the United States was published in Volume 2, article number 29 of the journal Immunity & Inflammation on June 30, 2026.

9 Jul 2026

Innovative polysaccharide hydrogels offer new hope for healing wounds

Announcing a new article publication in BIO Integration. Skin wound healing, especially in chronic non-healing conditions, such as diabetic foot ulcers and infected wounds, remains a formidable clinical challenge due to the complex pathophysiologic mechanisms and prolonged repair processes.

7 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

Engineered CAR T cells successfully target bladder cancer in mice

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

26 Jun 2026

Peacemaker immune cells offer new hope for restoring immune tolerance

'Peacemaker' immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune tolerance, according to a new paper in Frontiers in Science.

25 Jun 2026

Study reveals different factors driving rising neurological disease rates

The growing number of people living with Parkinson's disease (PD), multiple sclerosis (MS) and motor neuron disease (MND) is being driven by different underlying factors, according to new research due to be presented at the European Academy of Neurology (EAN) Congress 2026 and published in Neurology.

15 Jun 2026

Laverock Therapeutics reports key oncology research milestones

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications.

From Laverock Therapeutics 10 Jun 2026

New findings highlight risks and therapeutic targets in systemic sclerosis

Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs.

7 Jun 2026

EULAR 2026 highlights rising comorbidity risks in rheumatic disease

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures.

4 Jun 2026

Blocking sugar modification could boost breast cancer immunotherapy success

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor.

27 May 2026

Silica nanoparticles dampen early allergy signals in mouse mast cells

This in vitro study found that negatively charged SiO2 nanoparticles suppressed antigen-induced degranulation and activation-marker changes in IgE-sensitized mouse bone marrow-derived mast cells. By contrast, mTiO2 nanoparticles showed cytotoxic and pro-inflammatory effects, including enhanced DNP-induced IL-6 release, suggesting nanoparticle composition can shape early allergic immune responses.

24 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Stem cell infusions improve symptoms in butterfly skin disease

The intravenous infusion of mesenchymal stem cells from family donors is safe and improves symptoms such as pruritus (itching), sleep disturbances, and fatigue associated with Recessive Dystrophic Epidermolysis Bullosa (RDEB), popularly known as "butterfly skin".

18 May 2026